Prof. Sherven Sharma

University of California, USA

Email: ssharma@mednet.ucla.edu

Qualifications

1993 Ph.D., University of Southern California

1983 B.Sc., University of the South Pacific

Publications (selected)

1. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum soluble E-cadherin. J Thorac. Oncol. 2008; 3(2): 117-124.
2. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009 Jun 1;182(11): 6951-8.
3. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med. 2008 Jul 22;6: 38.
4. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008 Dec 1;5(8): 811-5.
5. Sharma S, Andersson A. Adenovirus E3 proteins help tumors to evade innate and adaptive immune responses. Cancer Biol Ther. 2009 Jun 2;8(12). [Epub ahead of print]
6. Veena MS, Qin M, Andersson A, Sharma S, Batra RK. CAR mediates efficient tumor engraftment of mesenchymal type lung cancer cells. Lab Invest. 2009 Jun 8. [Epub ahead of print]
7. Basak SK, Veena MS, Oh S, Huang G, Srivatsan E, Huang M, Sharma S, Batra RK. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One. 2009 Jun 12;4(6): e5884.
8. Towards effective immunotherapy for Lung Cancer: Simultaneous targeting of tumor initiating cells and immune pathways in the tumor microenvironment. Dubinett and Sharma. Future Medicine, Immunotherapy 2009 1(5) 721-725.
9. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, Chia D, Goodglick L, Elashoff DA, Luo J, Magyar CE, Dohadwala M, Lee JM, St John MA, Strieter RM, Sharma S, Dubinett SM. Clin Cancer Res. 2009 Nov 15;15(22): 6820-9. Epub 2009 Nov 3.
10. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, Lai C, Abemayor E, Fishbein M, Elashoff DA, Sharma S, Dubinett SM. Clin Cancer Res. 2009 Oct 1;15(19): 6018-27. Epub 2009 Sep 29.
11. Chemokines: can effector cells be redirected to the site of the tumor? Dubinett SM, Lee JM, Sharma S, Mulé JJ. Cancer J. 2010 Jul-Aug;16(4): 325-35.
12. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, Münz M. PLoS One. 2010 Oct 18;5(10): e13474. PMID: 20976159. PMCID: PMC2956687.
13. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, Dubinett SM, Rome LH, Sharma S. PLoS One. 2011 May 3;6(5): e18758.
14. Role of CXCR3 ligands in IL-7/IL-7R{alpha}-Fc-mediated antitumor activity in lung cancer. Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. Clin Cancer Res. 2011 Jun 1;17(11): 3660-72. PMCID: PMC3118413.
15. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. Expert Opin Biol Ther. 2011 Aug;11(8): 987-90. PMCID: PMC3132083.